- ►nih.gov RS Braithwaite, RT Chlebowski, J Lau, S … - Journal of general internal medicine, 2003 - Springer OBJECTIVE: Tamoxifen reduces the risk of developing breast cancer but also
affects the risks of certain vascular and neo- plastic events. Our purpose was
to estimate the effects of tamoxifen on potentially life-threatening ... Cited by 141 - Related articles - BL Direct - All 9 versions
R Clarke, MC Liu, KB Bouker, Z Gu, RY Lee, Y … - Oncogene, 2003 - nature.com Antiestrogens include agents such as tamoxifen, toremifene, raloxifene, and
fulvestrant. Currently, tamoxifen is the only drug approved for use in breast
cancer chemoprevention, and it remains the treatment of choice for most ... Cited by 124 - Related articles - BL Direct - All 4 versions
- ►endocrinology-journals.org [PDF] IH Hamelers, PH Steenbergh - Endocrine-related cancer, 2003 - Soc Endocrinology Estrogens and insulin-like growth factors (IGFs) act as mitogens promoting cell
proliferation in normal breast tissue as well as in breast carcinomas. Both
hormones have been shown to play a role in the development of breast cancer ... Cited by 61 - Related articles - BL Direct - All 4 versions
- ►aacrjournals.org SM Lippman, WK Hong - Cancer Research, 2002 - AACR A few decades ago, cardiology shifted research and treatment paradigms to absorb
prevention as a major arm of its science and practice. Cardiology moved beyond
exclusively treating major cardiovascular disease events (eg., acute ... Cited by 58 - Related articles - BL Direct - All 3 versions
- ►jcojournal.org BK Dunn, DL Wickerham, LG Ford - Journal of Clinical Oncology, 2005 - jcojournal.org Carcinogenesis in the breast is a hormonally dependent process. Evidence
implicating estrogen as a key breast carcinogen comes from various lines of
investigation. Traditional epidemiologic studies demonstrate associations ... Cited by 48 - Related articles - All 7 versions
- ►endocrinology-journals.org CJ Fabian, BF Kimler, MS Mayo, SA Khan - Endocrine-related cancer, 2005 - Soc Endocrinology Breast tissue and duct fluid provide a rich source of biomarkers to both aid in
the assessment of short-term risk of developing breast cancer and predict and
assess responses to prevention interventions. There are three methods ... Cited by 42 - Related articles - BL Direct - All 4 versions
- ►aacrjournals.org VG Vogel, JP Costantino, DL Wickerham, WM … - Clinical Cancer Research, 2003 - AACR Following up on the results of recent completed trials, several major breast
cancer prevention trials are either underway or impending. In the Study of
Tamoxifen and Raloxifene trial, eligible women are at least 35 years of age ... Cited by 39 - Related articles - BL Direct - All 5 versions
- ►inimed.com.mx [PDF] AB Hollingsworth, SE Singletary, M Morrow, … - The American Journal of Surgery, 2004 - Elsevier The potential for reducing the risk of breast cancer through selective estrogen
receptor modulators, aromatase inhibitors, and surgery has generated interest in
the use of quantitative models of risk assessment. With the addition of ... Cited by 39 - Related articles - All 5 versions
J Tchou, N Hou, A Rademaker, VC Jordan, M … - CA A Cancer Journal for Clinicians - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 38 - Related articles - BL Direct - All 3 versions
